nach oben

Erschienen in:

29.03.2018 | Original Article

Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients

verfasst von: Freddy Caldera, Sumona Saha, Arnold Wald, Christine A. Garmoe, Sue McCrone, Bryant Megna, Dana Ley, Mark Reichelderfer, Mary S. Hayney

Erschienen in: Digestive Diseases and Sciences | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with inflammatory bowel disease (IBD) are often immunosuppressed, and those patients receiving anti-tumor necrosis factor α (TNF) therapy can have lower antibody responses to vaccines. Pertussis cases are at their highest levels in the post-vaccine era. There is little data regarding responses to the Tdap (tetanus, diphtheria, and acellular pertussis) vaccine in IBD patients.

Aims

The aim of this study was to compare sustained vaccine-induced Tdap antibody concentrations in a cohort of IBD patients stratified by medication regimens with healthy controls (HC) who had received an adult Tdap booster.

Methods

We performed a cross-sectional study evaluating antibody responses to Tdap vaccine among IBD patients compared to HC. Our study consisted of three patient groups: adults with IBD stratified by maintenance medication regimen: (1) thiopurine monotherapy; (2) anti-TNF monotherapy; and (3) combination therapy (anti-TNF and immunomodulator (thiopurine or methotrexate)).

Results

Ninety IBD patients and 20 HC participated. Pertussis pertactin antibody concentrations were significantly lower in IBD patients (p = 0.021) compared to HC, and those on anti-TNF agents (monotherapy or combination) had lower antibody concentrations compared to those on thiopurine monotherapy (p = 0.028). Diphtheria antibody concentrations were also lower in IBD patients (p < 0.001), and those on anti-TNF agents (monotherapy or combination) had lower antibody concentrations compared to the thiopurine monotherapy group (p < 0.001).

Conclusion

IBD patients on anti-TNF agents had lower antibody concentrations to diphtheria and pertussis. These findings suggest a need for different Tdap booster schedules for IBD patients on anti-TNF therapy.

Clinical Trials Registry NCT02434133.

Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT. American gastroenterological association institute guideline on the use of thiopurines, methotrexate, and anti–TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145:1459–1463.CrossRefPubMed

Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241–258.CrossRefPubMed

Roush SW, Murphy TV, Vaccine-Preventable Disease Table Working Group a. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the united states. JAMA. 2007;298:2155–2163.CrossRefPubMed

Kantsone I, Lucenko I, Perevoscikovs J. More than 20 years after re-emerging in the 1990s diphtheria remains a public health problem in Latvia. Eurosurveillance. 2016;21:30414.CrossRefPubMedPubMedCentral

Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older, United States, 2017. Ann Intern Med. 2017;166:209–219.CrossRefPubMed

Wagner KS, White JM, Andrews NJ, et al. Immunity to tetanus and diphtheria in the UK in 2009. Vaccine. 2012;30:7111–7117.CrossRefPubMed

Hammarlund E, Thomas A, Poore EA, et al. Durability of vaccine-induced immunity against tetanus and diphtheria toxins: a cross-sectional analysis clinical infectious. Diseases. 2016;62:1111–1118.

Centers for Disease Control and Prevention. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend Rep.

Center for Disease Control. Pertussis cases by year (1922–2015). Available at: https://www.cdc.gov/pertussis/surv-reporting/cases-by-year.html; Accessed 31.10.17.

10.

European Centre for Disease Prevention and Control. Annual epidemiological report pertussis 2014 data reported on July 7 2016. Available at: http://ecdc.europa.eu/en/healthtopics/pertussis/Pages/Annual-epidemiological-report-2016.aspx; 2017 Accessed 31.10.17.

11.

Winter K, Harriman K, Zipprich J, et al. California pertussis epidemic, 2010. J Pediatr. 2012;161:1091–1096.CrossRefPubMed

12.

Acosta AM, DeBolt C, Tasslimi A, et al. Tdap vaccine effectiveness in adolescents during the 2012 washington state pertussis epidemic. Pediatr. 2015;135:981–989.CrossRef

13.

Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis. 2012;18:261–268.CrossRefPubMed

14.

Dezfoli S, Horton HA, Thepyasuwan N, et al. Combined immunosuppression impairs immunogenicity to tetanus and pertussis vaccination among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1754–1760.CrossRefPubMed

15.

Cullen G, Bader C, Korzenik JR, Sands BE. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut. 2012;61:385–391.CrossRefPubMed

16.

Banaszkiewicz A, Gawronska A, Klincewicz B, et al. Immunogenicity of pertussis booster vaccination in children and adolescents with inflammatory bowel disease: a controlled study. Inflamm Bowel Dis. 2017;23:847–852.CrossRefPubMed

17.

Wisconsin Department of Health Services. Wisconsin Immunization Registry (WIR). Available at: https://www.dhs.wisconsin.gov/immunization/wir.htm; 2017 Accessed 31.10.17.

18.

Hodder SL, Cherry JD, Mortimer JEA, Ford AB, Gornbein J, Papp K. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis. 2000;31:7–14.CrossRefPubMed

19.

Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16:1907–1916.CrossRefPubMed

20.

Rohde KA, Cunningham KC, Henriquez KM, Nielsen AR, Worzella SL, Hayney MS. A cross-sectional study of tetanus and diphtheria antibody concentrations post vaccination among lung transplant patients compared with healthy individuals. Transpl Inf Dis. 2014;16:871–877.CrossRef

21.

Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055–1065.CrossRefPubMedPubMedCentral

22.

Dominicus R, Galtier F, Richard P, Baudin M. Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax^®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis^®) in adults aged ≥ 40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years. Vaccine. 2014;32:3942–3949.CrossRefPubMed

23.

John T, Voysey M, Yu LM, et al. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: a 5-year follow-up of a randomised controlled study. Vaccine. 2015;33:4579–4585.CrossRefPubMed

24.

Marshall GS, Pool V, Greenberg DP, Johnson DR, Sheng X, Decker MD. Safety and immunogenicity of tetanus-diphtheria-acellular pertussis vaccine administered to children 10 or 11 years of age. Clin Vaccine Immunol. 2014;21:1560–1564.CrossRefPubMedPubMedCentral

25.

Weston WM, Friedland LR, Wu X, Howe B. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix^®): results of two randomized trials. Vaccine. 2012;30:1721–1728.CrossRefPubMed

26.

Cleveland NK, Rodriquez D, Wichman A, Pan I, Melmed GY, Rubin DT. Many inflammatory bowel disease patients are not immune to measles or pertussis. Dig Dis Sci. 2016;61:2972–2976.CrossRefPubMed

27.

Euopean Centre for Disease Prevention and Control. Vaccine Schedule. Available at: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx; 2017 Accessed 31.10.17.

28.

Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn’s Colitis. 2014;8:443–468.CrossRef

29.

Schwartz KL, Kwong JC, Deeks SL, et al. Effectiveness of pertussis vaccination and duration of immunity CMAJ. Can Med Assoc J. 2016;188:E399–E406.CrossRef

Titel: Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients
verfasst von: Freddy Caldera
Sumona Saha
Arnold Wald
Christine A. Garmoe
Sue McCrone
Bryant Megna
Dana Ley
Mark Reichelderfer
Mary S. Hayney
Publikationsdatum: 29.03.2018
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 6/2018
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-018-5043-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients

Abstract

Background

Aims

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Background

Aims

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease

Role of Positron Emission Tomography in Assessing Disease Activity in Ulcerative Colitis: Comparison with Biomarkers

Mast Cells and Serotonin Synthesis Modulate Chagas Disease in the Colon: Clinical and Experimental Evidence

Concise Commentary: Visceral Obesity, Sarcopenia, and Cancer Surgery—Increasing Fitness Decreases Risk

Risk of Neoplastic Progression Among Patients with an Irregular Z Line on Long-Term Follow-Up

Profiles of Patients Who Use Marijuana for Inflammatory Bowel Disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin